VECT | VectivBio Holding AG | [NASD]
Index- P/E- EPS (ttm)-1.87 Insider Own4.50% Shs Outstand62.74M Perf Week0.86%
Market Cap1.03B Forward P/E- EPS next Y-1.94 Insider Trans0.00% Shs Float59.92M Perf Month55.86%
Income-93.70M PEG- EPS next Q- Inst Own57.00% Short Float / Ratio0.97% / 0.87 Perf Quarter86.32%
Sales27.34M P/S37.66 EPS this Y10.70% Inst Trans0.32% Short Interest0.58M Perf Half Y99.39%
Book/sh4.02 P/B4.07 EPS next Y- ROA-50.50% Target Price17.83 Perf Year199.45%
Cash/sh3.52 P/C4.65 EPS next 5Y16.50% ROE-61.30% 52W Range4.25 - 16.63 Perf YTD88.69%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-1.68% Beta-
Dividend %- Quick Ratio9.10 Sales past 5Y- Gross Margin- 52W Low284.71% ATR0.83
Employees42 Current Ratio9.10 Sales Q/Q- Oper. Margin- RSI (14)82.17 Volatility1.97% 5.79%
OptionableNo Debt/Eq0.05 EPS Q/Q4.00% Profit Margin- Rel Volume1.03 Prev Close16.28
ShortableYes LT Debt/Eq0.05 EarningsApr 19 BMO Payout- Avg Volume664.22K Price16.35
Recom2.60 SMA2031.33% SMA5056.98% SMA200100.33% Volume660,173 Change0.43%
Date Action Analyst Rating Change Price Target Change
Dec-13-22Initiated Jefferies Buy $18
Jul-01-22Initiated Piper Sandler Overweight $23
May-04-21Initiated SVB Leerink Outperform $28
May-04-21Initiated Credit Suisse Outperform $24
May-04-21Initiated BofA Securities Buy $19
May-23-23 12:07PM
May-22-23 05:43PM
09:43AM Loading…
May-10-23 08:59AM
Apr-22-23 08:06AM
Apr-19-23 07:05AM
Apr-12-23 08:00AM
Mar-13-23 08:00AM
Mar-09-23 05:05AM
Dec-09-22 04:01PM
06:27AM Loading…
Nov-24-22 06:27AM
Nov-16-22 07:30AM
Nov-09-22 08:28AM
Nov-03-22 07:01AM
Oct-18-22 08:30AM
Oct-14-22 07:34AM
Oct-13-22 07:20AM
Oct-12-22 10:00AM
Aug-11-22 06:45AM
Jun-29-22 07:15AM
Jun-14-22 09:03PM
Jun-09-22 04:16PM
08:15AM Loading…
Jun-02-22 08:15AM
May-09-22 07:30AM
Apr-21-22 07:15AM
Apr-07-22 07:15AM
Mar-30-22 08:04AM
Mar-29-22 07:45AM
Mar-23-22 07:15AM
Feb-08-22 07:15AM
Jan-18-22 10:11AM
Jan-05-22 10:14AM
Nov-10-21 08:30AM
Nov-04-21 07:15AM
Oct-20-21 07:15AM
Sep-21-21 07:15AM
Sep-16-21 07:15AM
Sep-08-21 07:15AM
Sep-03-21 07:15AM
Aug-31-21 07:00AM
Aug-12-21 07:15AM
Jul-12-21 07:15AM
Jul-09-21 06:51AM
Jun-24-21 07:19AM
Jun-15-21 07:15AM
May-25-21 07:15AM
Apr-13-21 09:53PM
Apr-09-21 12:32PM
Apr-08-21 10:27PM
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland.